"L’Istituto Oncologico della Svizzera Italiana (IOSI) raggruppa in un’unica struttura organizzativa tutte le specialità non chirurgiche che all’interno dell’Ospedale multisito EOC si occupano di tumori. Lo IOSI è basato sul modello del “Comprehensive Cancer Centre”, anche se la sua struttura è adattata alla realtà del Ticino, coprendo in modo trasversale tutto l’Ospedale multisito EOC. Lo IOSI raggruppa quindi le specialità che si occupano di diagnosi, terapia e ricerca nell’ambito delle malattie tumorali. Lo IOSI propone ai suoi pazienti un approccio olistico e la possibilità di fruire dei più recenti progressi della ricerca oncologica. Grazie a tutto ciò, lo IOSI è diventato un centro di riferimento anche al di là dei confini nazionali."
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
Clinical Trials at Ospedale San Giovanni; Oncologia
During the past decade, Ospedale San Giovanni; Oncologia conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale San Giovanni; Oncologia"
#1 collaborator was "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Ospedale San Giovanni; Oncologia
According to Clinical.Site data, the most researched conditions in "Ospedale San Giovanni; Oncologia" are
"Breast Neoplasms" (1 trials), "Diffuse Large B-Cell Lymphoma" (1 trials) and "Non-Hodgkin's Lymphoma" (1 trials). Many other conditions were trialed in "Ospedale San Giovanni; Oncologia" in a lesser frequency.
Clinical Trials Intervention Types at Ospedale San Giovanni; Oncologia
Most popular intervention types in "Ospedale San Giovanni; Oncologia" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (2 trials), "Chemotherapy (Induction Period)" (1 trials), "Cyclophosphamide" (1 trials), "Doxorubicin" (1 trials) and "Herceptin" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Ospedale San Giovanni; Oncologia
The vast majority of trials in "Ospedale San Giovanni; Oncologia" are
3 trials for "All" genders.
Clinical Trials Status at Ospedale San Giovanni; Oncologia
Currently, there are NaN active trials in "Ospedale San Giovanni; Oncologia".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Ospedale San Giovanni; Oncologia,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Ospedale San Giovanni; Oncologia, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".